Cleerly
Get twice-weekly insights on the biggest stories shaping cardiology.
You might also like
Pharmaceuticals December 9, 2024
Tirzepatide Triumphant Over Semaglutide December 9, 2024
Topline results from the SURMOUNT-5 trial found Eli Lilly’s tirzepatide led to far greater weight loss than Novo Nordisk’s semaglutide, giving Lilly a boost in the race to become America’s go-to GLP-1. Over SURMOUNT-5’s 72 week duration, 751 participants across the U.S. and Puerto Rico were randomized to receive the maximum tolerated dose of tirzepatide […]
Pharmaceuticals December 5, 2024
MariTide’s Weight Loss Milestone December 5, 2024
The red hot weight loss segment just got even hotter, as the Phase 2 trial of Amgen’s maridebart cafraglutide (MariTide) yielded exceptional body mass reductions among people with obesity and T2D, propelling the pharma giant closer to FDA approval. Building on this earlier success, Amgen’s new Phase 2 trial lasted 52 weeks and enrolled patients […]
Pharmaceuticals December 2, 2024
Winrevair’s Big PAH Win December 2, 2024
Stunning topline results from Merck Winrevair’s Phase 3 ZENITH trial found that the drug significantly reduced morbidity and mortality risks in patients with pulmonary arterial hypertension, paving the way for stronger commercialization and further functional trials. The ZENITH trial randomized 172 patients to either receive Winrevair and background PAH therapy, or placebo and PAH therapy. […]
